-
公开(公告)号：US12090179B2
公开(公告)日：2024-09-17
申请号：US18159934
申请日：2023-01-26
申请人： Salspera, LLC
发明人： Daniel A. Saltzman
IPC分类号： A61K35/74 , A61K31/513 , A61K31/555 , A61K31/675 , A61K31/7068 , A61K33/243
CPC分类号： A61K35/74 , A61K31/513 , A61K31/555 , A61K31/675 , A61K31/7068 , A61K33/243
摘要： A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
-
2.发明公开公开(公告)号：US20240299356A1
公开(公告)日：2024-09-12
申请号：US18547871
申请日：2022-02-25
发明人： Steven ALTSCHULER , Lani WU , Xiaoxiao SUN , Matthew JACOBSON
IPC分类号： A61K31/415 , A61K31/40 , A61K31/506 , A61K31/517 , A61K31/555 , A61K31/7068
CPC分类号： A61K31/415 , A61K31/40 , A61K31/506 , A61K31/517 , A61K31/555 , A61K31/7068
摘要： Provided herein are, inter alia, methods and composition for the treatment of cancers that are recalcitrant to treatment and/or become resistant to certain drug treatments. The methods provided may, inter alia, be used to treat cancer in subjects having elevated STAT1 activity levels.
-
公开(公告)号：US20240254226A1
公开(公告)日：2024-08-01
申请号：US18566424
申请日：2022-06-09
发明人： Tatsuya OKAMOTO
IPC分类号： C07K16/28 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61K39/00 , A61P35/00
CPC分类号： C07K16/2803 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/555 , A61P35/00 , A61K2039/507 , A61K2039/545
摘要： An effective cancer treatment method is disclosed. According to the cancer treatment method, a CD47 inhibitory substance, an immune checkpoint inhibitory substance (for example, an anti-PD-1 antibody), and a standard therapy (for example, a combination therapy in which Bevacizumab or Cetuximab is added to FOLFOX therapy for radically unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a dose-reduced regimen thereof for pancreatic cancer having distant metastasis) are combined. The treatment method is useful for cancer treatment.
-
公开(公告)号：US12048732B2
公开(公告)日：2024-07-30
申请号：US16093508
申请日：2017-04-14
发明人： Stacey J. Hansen , Julia E. Novak
IPC分类号： A61K38/17 , A61K9/00 , A61K31/337 , A61K31/502 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/704 , A61K33/243 , A61K47/64 , A61K49/00 , A61P35/00 , C07K14/00 , C07K14/435
CPC分类号： A61K38/1767 , A61K9/0019 , A61K31/337 , A61K31/502 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/704 , A61K33/243 , A61K47/6415 , A61K49/0032 , A61K49/0056 , A61P35/00 , C07K14/00 , C07K14/43522
摘要： Compositions and formulations comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to detectable agents or active agents. Methods of detecting and treating ductal carcinoma in situ breast cancer, invasive ductal carcinoma breast cancer, lobular carcinoma in situ, invasive lobular carcinoma, and triple-negative breast cancer with chlorotoxin conjugate compounds are also provided, including methods of imaging tumor tissues and cells.
-
公开(公告)号：US20240245682A1
公开(公告)日：2024-07-25
申请号：US18395241
申请日：2023-12-22
发明人： Timothy D. MACHAJEWSKI , Darren FINKELSTEIN , Timothy F. HOM , Dennis MONTELEONE , Manuel Angel MUNOZ , Katerina LEFTHERIS
IPC分类号： A61K31/501 , A61K31/337 , A61K31/4375 , A61K31/4745 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/555 , A61K31/7068 , A61P35/00 , C07D471/04 , G01N33/50
CPC分类号： A61K31/501 , A61K31/337 , A61K31/4375 , A61K31/4745 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/555 , A61K31/7068 , A61P35/00 , C07D471/04 , G01N33/5011 , G01N2333/57 , G01N2333/96436
摘要： The disclosure relates to compounds of formula (A) and formula (I), e.g.:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of αVβ8, αVβ1, and αVβ6 integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof.-
公开(公告)号：US20240148896A1
公开(公告)日：2024-05-09
申请号：US18356901
申请日：2023-07-21
发明人： Paul Fisher , Paulina Davis
IPC分类号： A61K47/69 , A61K9/00 , A61K9/06 , A61K9/14 , A61K9/70 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/245 , A61K31/522 , A61K31/555 , A61K31/606 , A61K31/675 , A61K31/704 , A61K45/06 , A61K47/08 , A61K47/34 , A61K47/55 , A61K47/59 , A61K47/60
CPC分类号： A61K47/6903 , A61K9/0019 , A61K9/06 , A61K9/14 , A61K9/7007 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/245 , A61K31/522 , A61K31/555 , A61K31/606 , A61K31/675 , A61K31/704 , A61K45/06 , A61K47/08 , A61K47/34 , A61K47/55 , A61K47/59 , A61K47/60
摘要： Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.
-
公开(公告)号：US20240148748A1
公开(公告)日：2024-05-09
申请号：US18511413
申请日：2023-11-16
申请人： Nutrition21, LLC
发明人： James R. Komorowski
IPC分类号： A61K31/555 , A23L33/125 , A23L33/16 , A23L33/165 , A23L33/17 , A61K9/08 , A61K9/14 , A61K31/198 , A61K31/718 , A61K31/732 , A61K33/24 , A61K36/899 , A61K38/01 , A61K45/06
CPC分类号： A61K31/555 , A23L33/125 , A23L33/16 , A23L33/165 , A23L33/17 , A61K9/08 , A61K9/14 , A61K31/198 , A61K31/718 , A61K31/732 , A61K33/24 , A61K36/899 , A61K38/018 , A61K45/06 , A23V2002/00
摘要： Administration of certain chromium complexes in combination with a starch provide unexpected benefits regarding increasing amino acid absorption, protein synthesis, exercise tolerance, lean muscle mass, skeletal muscle hypertrophy, muscle power, muscle endurance, muscle strength, FSR, and decreasing delayed onset muscle soreness, muscle protein breakdown, and fat mass.
-
公开(公告)号：US20240123082A1
公开(公告)日：2024-04-18
申请号：US18327658
申请日：2023-06-01
发明人： Paul Fisher , Paulina Davis
IPC分类号： A61K47/69 , A61K9/00 , A61K9/06 , A61K9/14 , A61K9/70 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/245 , A61K31/522 , A61K31/555 , A61K31/606 , A61K31/675 , A61K31/704 , A61K45/06 , A61K47/08 , A61K47/34 , A61K47/55 , A61K47/59 , A61K47/60
CPC分类号： A61K47/6903 , A61K9/0019 , A61K9/06 , A61K9/14 , A61K9/7007 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/245 , A61K31/522 , A61K31/555 , A61K31/606 , A61K31/675 , A61K31/704 , A61K45/06 , A61K47/08 , A61K47/34 , A61K47/55 , A61K47/59 , A61K47/60
摘要： Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.
-
公开(公告)号：US11951147B2
公开(公告)日：2024-04-09
申请号：US17735776
申请日：2022-05-03
申请人： Medivir AB
IPC分类号： A61K38/05 , A61K31/404 , A61K31/555 , A61K38/07 , A61K45/06 , A61N5/06 , A61N5/10 , A61P35/00 , A61P35/04 , C07D403/06 , C07D403/14 , C07K5/02 , C07K5/06 , C07K5/062 , C12N5/09 , A61K38/00
CPC分类号： A61K38/05 , A61K31/404 , A61K31/555 , A61K38/07 , A61K45/06 , A61N5/062 , A61N5/10 , A61P35/00 , A61P35/04 , C07D403/06 , C07D403/14 , C07K5/02 , C07K5/06 , C07K5/06026 , C12N5/0693 , A61K38/00 , C12N2500/46 , Y02P20/55
摘要： A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
-
公开(公告)号：US11944626B2
公开(公告)日：2024-04-02
申请号：US16311533
申请日：2017-06-20
申请人： The Regents of the University of Michigan , Indiana University Research and Technology Corporation
IPC分类号： A61K31/519 , A61K31/337 , A61K31/4745 , A61K31/522 , A61K31/555 , A61K31/7068 , A61K39/395 , A61K45/06 , A61P31/00 , A61P35/00 , C07D487/04
CPC分类号： A61K31/519 , A61K31/337 , A61K31/4745 , A61K31/522 , A61K31/555 , A61K31/7068 , A61K39/395 , A61K45/06 , A61P31/00 , A61P35/00 , C07D487/04 , A61K31/522 , A61K2300/00 , A61K31/555 , A61K2300/00 , A61K31/337 , A61K2300/00 , A61K31/4745 , A61K2300/00 , A61K31/7068 , A61K2300/00
摘要： This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.
-
-
-
-
-
-
-
-
-
搜索结果
3017 条记录 (耗时 0.03 秒)
